Publications by authors named "J Mallolas"
Article Synopsis
- Study aimed to explore how common liver steatosis (LS) and liver fibrosis (LF) are among people with HIV, and what factors contribute to these liver conditions.
- In a large cohort study involving over 4,600 people, it was found that 28% showed signs of LS, with this prevalence increasing to 55% in a group with higher cardiovascular risk factors; LF was less common, affecting only about 1-5% across different assessment methods.
- Key factors linked to LS included current CD4 counts and conditions like diabetes and hypertension, while past use of certain HIV drugs was linked to LF; notably, current treatment with integrase strand transfer inhibitors appeared protective against LF.
Article Synopsis
- The study examined SARS-CoV-2 infection rates and risk factors among unvaccinated people living with HIV (PWH), finding an 18% prevalence of infection in this group.
- It involved testing plasma samples from 4,400 PWH and revealed that a significant portion of those infected were asymptomatic or had mild symptoms.
- The research concluded that common risk factors included younger age, female sex, MSM status, and syphilis history, while antiretrovirals, including tenofovir, did not protect against SARS-CoV-2 infection.
Article Synopsis
- The study examines the impact of universal antiretroviral therapy (ART) on people living with HIV (PLHIV) admitted to the ICU, comparing data from 2006-2015 and 2016-2019.
- It found that more patients were on ART before admission after the recommendation was put in place, which led to fewer complications and lower ICU mortality rates (14% vs 7%).
- Key predictors of mortality included the severity of illness and complications during admission, highlighting that ART use during ICU stays offered some protection against mortality.
Introduction: Rapid initiation of ART after HIV diagnosis is recommended for individual and public health benefits. However, certain clinical and ART-related considerations hinder immediate initiation of therapy.
Methods: An open-label, single-arm, single-centre 48-week prospective clinical trial involving ART-naïve HIV-diagnosed adults who started bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) within a week from the first hospital visit, before the availability of baseline laboratory and genotype results.
Background: The use of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) is based on the results of robust clinical trials.
Objectives: To assess the effectiveness and safety of BIC/FTC/TAF in treatment-naïve (TN) and treatment-experienced (TE) people with HIV using available real-world cohort studies.
Methods: Systematic review and meta-analysis of publications and communications identified via Boolean search in Medline, PubMed and Embase, and conference abstracts reporting retrospective real-world use of BIC/FTC/TAF, published until 31 January 2024.